Zacks Investment Research upgraded shares of SYNAGEVA BIOPHM (GEVA) from UNDERPERFORM to NEUTRAL on May 14, 2012, with a target price of $37.80.
Synageva BioPharma Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Its SBC-102 is an enzyme replacement therapy for Lysosomal Acid Lipase Deficiency, a lysosomal storage disorder. Synageva BioPharma Corp., formerly known as AviGenics, Inc., is headquartered in Lexington, Massachusetts with production facilities in Athens, Georgia.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SYNAGEVA BIOPHM (GEVA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment